BR9913183A - Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica - Google Patents

Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica

Info

Publication number
BR9913183A
BR9913183A BR9913183-8A BR9913183A BR9913183A BR 9913183 A BR9913183 A BR 9913183A BR 9913183 A BR9913183 A BR 9913183A BR 9913183 A BR9913183 A BR 9913183A
Authority
BR
Brazil
Prior art keywords
compound
treat
prepare
human
pharmaceutical composition
Prior art date
Application number
BR9913183-8A
Other languages
English (en)
Inventor
Brian Cox
Mark Patrick Healy
Deborah Wild
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR9913183A publication Critical patent/BR9913183A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSTO, USO DO MESMO, PROCESSO PARA PREPARá-LO, PROCESSO PARA TRATAR UM INDIVìDUO HUMANO OU ANIMAL, E, COMPOSIçãO FARMACêUTICA". Um composto de fórmula (I) em que R¹ é fenila substituída por um ou mais átomos de halogênio; R² é -NH~ 2~; R³ é -NH~ 2~ ou hidrogênio; R^ 4^ é -CXNR^ a^R^ b^, -CXNH-(CH~ 2~)~ y~-NR^ a^R^ b^; em que X é = O ou = S; y é um zero inteiro zero, 1 ou 2; R^ a^ e R^ b^, que podem ser iguais ou diferentes, são selecionados de hidrogênio e C1-C4-alquila ou juntos com o átomo de nitrogênio a que eles são ligados formam um heterociclo de 5- ou 6 membros, contendo um ou dois heteroátomos, heterociclo este podendo ser mais substituído com um ou mais grupos C1-C4-alquila; e seus derivados farmaceuticamente aceitáveis.
BR9913183-8A 1998-08-28 1999-08-26 Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica BR9913183A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9818881.6A GB9818881D0 (en) 1998-08-28 1998-08-28 Compounds
PCT/EP1999/006248 WO2000012488A1 (en) 1998-08-28 1999-08-26 Pyrazine compounds

Publications (1)

Publication Number Publication Date
BR9913183A true BR9913183A (pt) 2001-05-15

Family

ID=10838055

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913183-8A BR9913183A (pt) 1998-08-28 1999-08-26 Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica

Country Status (15)

Country Link
US (2) US6503909B1 (pt)
EP (1) EP1107960A1 (pt)
JP (1) JP2002523499A (pt)
KR (1) KR20010079696A (pt)
CN (1) CN1324349A (pt)
AU (1) AU5624999A (pt)
BR (1) BR9913183A (pt)
CA (1) CA2341543A1 (pt)
CO (1) CO5130006A1 (pt)
GB (1) GB9818881D0 (pt)
MA (1) MA26681A1 (pt)
PE (1) PE20001022A1 (pt)
TR (1) TR200100603T2 (pt)
TW (1) TW429255B (pt)
WO (1) WO2000012488A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500653A1 (en) * 2000-02-16 2005-01-26 Neurogen Corporation Substituted arylpyrazines
CN1231473C (zh) 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪
GB0010971D0 (en) 2000-05-05 2000-06-28 Glaxo Group Ltd Process
EP1501514B1 (en) * 2002-05-03 2012-12-19 Exelixis, Inc. Protein kinase modulators and methods of use
US7704995B2 (en) 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
CA2496197A1 (en) 2002-08-20 2004-03-04 Neurogen Corporation 5-substituted-2-arylpyrazines as modulators of crf receptors
EP1636270B1 (en) * 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005095613A1 (ja) * 2004-03-30 2005-10-13 Genomidea Inc. Rad51の発現抑制剤、該発現抑制剤を有効成分として含む医薬、及びその使用
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2008133722A2 (en) * 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
WO2023177233A1 (ko) * 2022-03-16 2023-09-21 (주)아름테라퓨틱스 신규한 화합물 및 이의 체크포인트 키나제 2 저해 용도
CN115611700B (zh) * 2022-10-11 2024-06-14 辽宁东大光明化工科技有限责任公司 一种1-溴-2,5-二氯-3-氟苯的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575975A (en) 1968-07-25 1971-04-20 Merck & Co Inc Process for the preparation of 3-aminopyrazinoylureas
US3544568A (en) * 1969-03-18 1970-12-01 Merck & Co Inc 3-amino-5,6-substituted pyrazinamides
US4402958A (en) 1981-11-19 1983-09-06 American Cyanamid Company Novel (substituted phenyl)-1,2,4-triazolo (4,3-A)pyrazines and novel 2-hydrazino-(substituted phenyl)pyrazine intermediates
MA26473A1 (fr) 1997-03-01 2004-12-20 Glaxo Group Ltd Composes pharmacologiquement actifs.

Also Published As

Publication number Publication date
US6503909B1 (en) 2003-01-07
KR20010079696A (ko) 2001-08-22
WO2000012488A1 (en) 2000-03-09
CO5130006A1 (es) 2002-02-27
GB9818881D0 (en) 1998-10-21
US20030022904A1 (en) 2003-01-30
TR200100603T2 (tr) 2001-07-23
JP2002523499A (ja) 2002-07-30
EP1107960A1 (en) 2001-06-20
MA26681A1 (fr) 2004-12-20
AU5624999A (en) 2000-03-21
TW429255B (en) 2001-04-11
PE20001022A1 (es) 2000-10-16
CA2341543A1 (en) 2000-03-09
CN1324349A (zh) 2001-11-28

Similar Documents

Publication Publication Date Title
BR9913183A (pt) Composto, uso do mesmo, processo para prepará-lo, processo para tratar um indivìduo humano ou animal, e, composição farmacêutica
BR0009702A (pt) Compostos ou seus sais, uso de compostos ou sais, e, formulações farmacêuticas
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
PT1263724E (pt) Novos compostos
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
BR0016420A (pt) Aminotiazóis inibidores de cinases dependentes de ciclinas
IT1311923B1 (it) Composti farmaceutici.
FI934274A0 (fi) N-sulfonyl-2-oxi-indolderivat, deras framstaellning och dessa innehaollande farmaceutiska kompositioner
ES2103479T3 (es) Derivados de anilida.
HUP0300616A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
GEP20032913B (en) Thienylazolylalcoxyethanamines, Their Preparation and Their Application as Medicaments
BR9604974A (pt) Composição farmacêutica contendo benzimidazol para inibir o crescimento de canceres
BR9813124A (pt) Compostos indol 2,3-substituìdos como inibidores cox-2
HUP0103203A2 (hu) Azaadamantánszármazékok és ezeket tartalmazó gyógyszerkészítmények
PT992509E (pt) Novos derivados macrolidos
BR9910448A (pt) Azóis solúveis em água como antifúngicos de amplo aspectro
NO942301L (no) Imidazokinazolinforbindelser og deres fremstilling og anvendelse
BR9814376A (pt) Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &4ß1, e, resina
BR0008321A (pt) Secretagogos de hormÈnio de crescimento
UA42733C2 (uk) Похідні біснафталіміду та їх фармацевтично прийнятні кислотно-адитивні солі, фармацевтична композиція з цитотоксичною активністю, яка їх містить
DE68921719D1 (de) Amphotericin B Derivate.
NO991581L (no) N-(benzotiazol-2-yl)piperidin-1-etanaminderivater, deres fremstilling og anvendelse i terapeutiske midler
BR0008130A (pt) Composto, composição farmacêutica, e, uso do composto ou de seu sal farmaceuticamente aceitável

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]